FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Addres	1 0		2. Issuer Name and Ticker or Trading Symbol <u>ISIS PHARMACEUTICALS INC</u> [ISIS]		tionship of Reporting Per all applicable) Director Officer (give title	10% Owner Other (specify			
(Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT			3. Date of Earliest Transaction (Month/Day/Year) 01/15/2015		below) SVP, Finance	below) & CFO			
(Street) CARLSBAD CA 92010		92010 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	,				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	01/15/2015	01/15/2015	M ⁽¹⁾		541 ⁽¹⁾	A	\$0	1,836	D	
Common Stock	01/16/2015	01/16/2015	S ⁽²⁾		207(2)	D	\$67.964	1,629	D	
Common Stock	01/15/2015	01/15/2015	M ⁽³⁾		313 ⁽³⁾	A	\$0	1,942	D	
Common Stock	01/16/2015	01/16/2015	S ⁽⁴⁾		120(4)	D	\$67.964	1,822	D	
Common Stock	01/15/2015	01/15/2015	M ⁽³⁾		654 ⁽³⁾	A	\$0	2,476	D	
Common Stock	01/16/2015	01/16/2015	S ⁽⁴⁾		250 ⁽⁴⁾	D	\$67.964	2,226	D	
Common Stock	01/15/2015	01/15/2015	M ⁽⁵⁾		1,875 ⁽⁵⁾	A	\$0	4,101	D	
Common Stock	01/16/2015	01/16/2015	S ⁽⁶⁾		714(6)	D	\$67.964	3,387	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Restricted Stock Units	(7)	01/15/2015	01/15/2015	A		5,518		(8)	(8)	Common Stock	5,518	\$0	5,518	D	
Restricted Stock Units	(7)	01/15/2015	01/15/2015	М			541 ⁽²⁾	(9)	(9)	Common Stock	541	\$0	541	D	
Restricted Stock Units	(7)	01/15/2015	01/15/2015	М			313 ⁽⁴⁾	(10)	(10)	Common Stock	313	\$0	624	D	
Restricted Stock Units	(7)	01/15/2015	01/15/2015	М			654 ⁽⁴⁾	(10)	(10)	Common Stock	654	\$0	1,307	D	
Restricted Stock Units	(7)	01/15/2015	01/15/2015	М			1,875 ⁽⁶⁾	(11)	(11)	Common Stock	1,875	\$0	5,625	D	

Explanation of Responses:

1. Acquired pursuant to vesting and release of shares pursuant to a RSU award granted on January 15, 2012.

2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2012.

3. Acquired pursuant to vesting and release of shares pursuant to a RSU award granted on January 15, 2013.

4. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013.

5. Acquired pursuant to vesting and release of shares pursuant to a RSU award granted on January 15, 2014.

6. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014.

7. Each Restricted Stock Unit represents a contingent right to receive one share of Isis common stock, or its equivalent cash value.

8. Grant 1/15/2015 to reporting person of Restricted Stock Units under the Isis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2016. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2019. The RSU is vested as to 0 shares on January 15, 2015.

9. Restricted Stock Unit Award granted on January 15, 2012. Restricted Stock Units vest in equal annual installments, the first installment vested on January 15, 2013. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2016.

10. Restricted Stock Unit Award granted on January 15, 2013. Restricted Stock Units vest in equal annual installments, the first installment vested on January 15, 2014. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2017.

11. Restricted Stock Unit Award granted on January 15, 2014. Restricted Stock Units vest in equal annual installments, the first installment vested on January 15, 2015. Upon vesting, the restricted stock units will be paid out in whole shares of Isis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2018. **Remarks:**

/s/Elizabeth Hougen

** Signature of Reporting Person

01/19/2015

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.